Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 05153U107 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
TCG Crossover GP II, LLC
13G
|
9.9% |
5/12/2026
Event 5/5/2026
|
||
| TCG Crossover GP II, LLC | 5.0% | |||
| TCG Crossover Fund II, L.P. | 5.0% | |||
| TCG Crossover GP III, LLC | 5.0% | |||
| TCG Crossover Fund III, L.P. | 5.0% | |||
| Chen Yu | 9.9% | |||
|
Adage Capital Management, L.P.
13G/A
|
8.4% |
8/12/2026
Event 6/30/2026
|
||
| Adage Capital Management, L.P. | 8.4% | |||
| Robert Atchinson | 8.4% | |||
| Phillip Gross | 8.4% | |||
|
Suvretta Capital Management, LLC
13G/A
|
7.6% |
8/13/2025
Event 6/30/2025
|
||
| Suvretta Capital Management, LLC | 7.6% | |||
| Averill Master Fund, Ltd. | 6.6% | |||
| Aaron Cowen | 7.6% | |||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
|
5.6% |
8/14/2026
Event 6/30/2026
|
||
| Frazier Life Sciences Public Fund, L.P. | 5.6% | |||
| FHMLSP, L.P. | 5.6% | |||
| FHMLSP, L.L.C. | 5.6% | |||
| Frazier Life Sciences X, L.P. | 0.1% | |||
| FHMLS X, L.P. | 0.1% | |||
| FHMLS X, L.L.C. | 0.1% | |||
| Frazier Life Sciences XI, L.P. | 0.3% | |||
| FHMLS XI, L.P. | 0.3% | |||
| FHMLS XI, L.L.C. | 0.3% | |||
| Frazier Life Sciences XII, L.P. | 0.8% | |||
| FHMLS XII, L.P. | 0.8% | |||
| FHMLS XII, L.L.C. | 0.8% | |||
| James N. Topper | 0.1% | |||
| Patrick J. Heron | 0.1% | |||
|
ForGrowth III PA B.V.
13G
|
5.1% |
10/1/2026
Event 9/25/2026
|
||
| ForGrowth III PA B.V. | 5.1% | |||
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 5.1% | |||
| Forbion Growth III Management B.V. | 5.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (5) | ||||
|
Long Focus Capital Management, LLC
13G
|
4.9% |
8/14/2026
Event 6/30/2026
|
||
| Long Focus Capital Management, LLC | 4.9% | |||
| John Helmers | 4.9% | |||
| BlackRock, Inc. 13G/A | 4.4% |
7/27/2026
Event 6/30/2026
|
||
|
Advent Life Sciences LLP
13G/A
|
3.3% |
2/17/2026
Event 2/13/2026
|
||
| Advent Life Sciences LLP | 3.3% | |||
| Advent Life Sciences Fund I LP | 3.3% | |||
| Rajesh Parekh, Ph.D. | 3.3% | |||
| Advent Life Sciences Fund III LP | 3.3% | |||
| ALS III Carry and Co-Invest LP | 3.3% | |||
| Advent-Harrington Impact Fund LP | 3.3% | |||
|
Eventide Asset Management, LLC
13G/A
|
0% |
5/14/2025
Event 3/31/2025
|
||
| Eventide Asset Management, LLC | 0% | |||
| Finny Kuruvilla, M.D. Ph. D. | 0% | |||
| Robin C. John | 0% | |||
|
Matrix Capital Management Company, LP
13D/A
|
0% |
5/11/2026
Event 5/7/2026
|
||
| Matrix Capital Management Company LP | 0% | |||
| David E. Goel | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 2.76 k | $17.3 k |
| 2026 Q2 | 151 | 98.3 M | $699 M |
| 2026 Q1 | 128 | 50.9 M | $340 M |
| 2025 Q4 | 118 | 50.2 M | $274 M |
| 2025 Q3 | 108 | 51.7 M | $319 M |
| 2025 Q2 | 107 | 50.7 M | $317 M |
| 2025 Q1 | 98 | 39.9 M | $232 M |
| 2024 Q4 | 98 | 39.4 M | $324 M |
| 2024 Q3 | 88 | 36.9 M | $329 M |
| 2024 Q2 | 82 | 41.1 M | $311 M |
| 2024 Q1 | 84 | 39.3 M | $309 M |
| 2023 Q4 | 79 | 39.5 M | $350 M |
| 2023 Q3 | 67 | 27.5 M | $254 M |
| 2023 Q2 | 63 | 27.1 M | $334 M |
| 2023 Q1 | 58 | 25.1 M | $233 M |
| 2022 Q4 | 51 | 24.1 M | $253 M |
| 2022 Q3 | 44 | 16.3 M | $296 M |
| 2022 Q2 | 45 | 15.8 M | $224 M |
| 2022 Q1 | 35 | 13.7 M | $299 M |
| 2021 Q4 | 33 | 13.1 M | $220 M |